Shareholder Proposal Challenges Visa's Gender-Affirming Healthcare Policies

The National Legal and Policy Center (NLPC) is set to present a shareholder proposal at Visa's annual meeting challenging the company's healthcare policies related to gender-transitioning treatments. The proposal seeks to investigate potential risks and compensation gaps in the company's current health benefits framework.

Claire Abernathy, a 20-year-old detransitioner, will address Visa's board of directors, sharing her personal experience of being guided into medical procedures at a young age. Abernathy claims that therapists and medical professionals rapidly facilitated her gender transition, beginning hormone treatments and recommending surgical interventions when she was as young as 12 years old.

The shareholder proposal highlights several medical procedures currently covered by Visa's health insurance through CIGNA, including mastectomies, penectomies, vaginectomies, orchiectomies, and salpingooophorectomies. NLPC argues that these coverage options potentially expose employees and their dependents to significant medical risks.

Paul Chesser, director of NLPC's Corporate Integrity Project, criticized the current approach, stating that corporations should reconsider funding what he describes as 'radical medical experiments' on workers and their children. The proposal suggests that with increasing detransitioner lawsuits against medical providers, corporations might soon face legal challenges.

The Equal Employment Opportunity Commission considers failure to provide equivalent benefits based on gender identity as discriminatory. Notably, the Securities and Exchange Commission previously acknowledged that de-transitioning individuals could be classified under such considerations of unfairness in corporate compensation practices.

NLPC has previously sponsored similar proposals at other major corporations, including Johnson & Johnson and PepsiCo, indicating a broader strategic approach to challenging corporate healthcare policies related to gender-affirming treatments.

Abernathy's testimony underscores the potential long-term psychological and physical consequences of rapid gender transition interventions, emphasizing the need for comprehensive medical evaluation and care that considers the full spectrum of potential outcomes.

The shareholder meeting represents a critical moment for examining corporate healthcare policies, potential medical risks, and the complex ethical considerations surrounding gender-affirming treatments.